Terminal2 — Card #38: Vascular Dementia (Advanced)

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of advanced vascular dementia at end of life. What the hospice team needs to understand on day one.

US Prevalence

1–4M

Vascular dementia is the second most common cause of dementia after Alzheimer's, accounting for 15–20% of all dementia cases in the US.^[1]

Survival from Diagnosis

3–5 yr

Median survival is shorter than Alzheimer's disease. Post-stroke dementia survival is closely tied to stroke recurrence and cardiac comorbidities.^[2]

Stepwise Decline Pattern

Unpredictable

Cognitive decline occurs in discrete steps tied to cerebrovascular events, separated by periods of relative stability — the defining clinical feature of vascular dementia.^[3]

Stroke Overlap Frequency

~30%

Approximately 30% of ischemic stroke survivors develop dementia within 3 months of the index stroke. Recurrent stroke substantially increases risk and accelerates stepwise decline.^[4]

Vascular dementia is caused by cerebrovascular disease — stroke, small vessel ischemic changes, or both — that damages brain tissue and disrupts cognitive function. Unlike Alzheimer's disease, where pathology is diffuse and amyloid-driven, vascular dementia reflects the cumulative injury of strokes, white matter ischemia, and lacunar infarcts to brain regions critical for cognition, behavior, and motor function. The result is a dementia with focal neurological deficits — hemiplegia, aphasia, dysphagia, pseudobulbar affect — that are not present in Alzheimer's and that require entirely different clinical management.^[1] At hospice enrollment, the patient with advanced vascular dementia is typically non-ambulatory, severely speech-limited or aphasic, incontinent, and dysphasic, with at least one qualifying comorbid condition such as aspiration pneumonia, recurrent urinary tract infection, septicemia, or pressure wounds.^[5]

The defining feature of vascular dementia that every hospice clinician must communicate to families is the stepwise decline pattern. Each new cerebrovascular event — whether a major cortical infarct, a lacunar infarct, or a silent ischemic event — produces a step down in cognitive and functional capacity, followed by a period of partial recovery or stable plateau. Families who have lived through five or six of these cycles have learned, painfully, not to trust the stable periods. This is not pessimism — it is experience, and it is one of the most psychologically costly features of any terminal illness. The hospice clinician who understands this is better equipped to communicate prognosis honestly, plan proactively, and support the family through what may be multiple acute events during the enrollment period.^[3]

Prevalence of vascular dementia is likely underestimated because it is frequently misclassified as Alzheimer's disease and because mixed dementia — concurrent vascular and Alzheimer's pathology — is present in up to 45% of autopsy dementia series and represents the most common pathological pattern in older adults with dementia.^[6] Cardiovascular risk factors — hypertension, atrial fibrillation, diabetes mellitus, hyperlipidemia, and smoking — are the primary modifiable contributors to cerebrovascular disease and remain clinically relevant at hospice enrollment because they shape both the patient's existing medication list and the family's complicated emotional relationship with the disease.

🧭 Clinical Framing: Two Tasks on Every First Visit

Vascular dementia hospice care has two clinical priorities that are unique to this diagnosis and that must both be completed at the first visit. First: reassess the cardiovascular medication burden — every antiplatelet, statin, antihypertensive, and anticoagulant must be evaluated against one question: does this medication reduce suffering or improve comfort right now? Most will not. Second: write the stroke event response protocol before another stroke happens. In vascular dementia, the next TIA or ischemic event is a clinical probability, not a possibility. A family without a documented response plan will call 911. Both tasks require the first visit — not the second.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The first thing I tell families at enrollment is this: stable does not mean better. In vascular dementia, stable is just the pause between the steps. Plan for the next step now, while things are quiet, because when it happens you will not have time to plan."

— Waldo, NP · Terminal2

S02Clinician

How It's Diagnosed

Diagnostic criteria, neuroimaging interpretation, and what to look for in prior records at hospice enrollment. Most patients arrive with an established diagnosis — this section helps you read it.

NINDS-AIREN Diagnostic Criteria

Guideline

The most widely used research criteria for vascular dementia. All three criteria must be met:^[7]

Dementia: Acquired cognitive decline causing functional impairment, not explained by delirium, severe aphasia alone, or other psychiatric disorder
Cerebrovascular disease: Documented by neuroimaging and/or focal neurological signs on examination — hemiparesis, Babinski sign, hemianopia, dysarthria, pseudobulbar palsy
Temporal relationship: Cognitive decline begins within 3 months of a recognized stroke, OR abrupt onset of cognitive decline, OR stepwise deterioration
Hospice relevance: At advanced stage, all three criteria are typically well-established in the prior records — the hospice clinician's task is to retrieve and document them, not re-establish them

DSM-5 Major Neurocognitive Disorder Due to Vascular Disease

Guideline

Significant cognitive decline in one or more domains from a prior level of performance, based on history and neuropsychological testing or clinical assessment^[8]
Functional interference: Cognitive deficits interfere with independence in everyday activities
Not exclusively delirious and not better explained by another mental disorder
Cerebrovascular etiology: Evidence from history, examination, or neuroimaging of cerebrovascular pathology sufficient to explain the cognitive deficits
Temporal pattern: Cognitive deficits temporally related to cerebrovascular events, OR evidence of decline in complex attention and frontal-executive function
Hospice note: The DSM-5 framework is the standard for clinical documentation — use it when updating the hospice plan of care to clarify the dementia subtype

Neuroimaging: What to Read in Prior Records

CT brain: Demonstrates established infarcts — cortical or subcortical wedge-shaped hypodensities following arterial territory (cortical infarcts) or small round hypodensities in basal ganglia, thalamus, internal capsule, pons (lacunar infarcts); adequate for establishing vascular pathology; most prior records will have at least one CT
MRI brain: More sensitive than CT for small vessel disease — look for periventricular and deep white matter T2 signal hyperintensities (white matter hyperintensities / WMH) and lacunar lesions; DWI sequence identifies acute infarcts when a new event is suspected
Fazekas scale: Grades white matter hyperintensity burden on MRI — 0 = absent; 1 = punctate foci; 2 = beginning confluence; 3 = large confluent areas; Fazekas 2–3 correlates with subcortical ischemic vascular dementia and higher cognitive and gait impairment burden^[9]
Strategic infarcts: A single infarct in a cognitively critical location — thalamus, caudate, hippocampus, genu of internal capsule — can produce dementia disproportionate to lesion size; look for thalamic or caudate lesions in records
Hospice action: No new neuroimaging is needed at hospice enrollment; the clinical picture and prior records are sufficient; neuroimaging for a new event in a comfort-only patient adds burden without changing management

Hospice Records Review Priorities

Stroke history: Document the number, timing, and neurological consequences of all prior stroke events — this is the patient's clinical biography and explains the current deficit pattern
Prior neuroimaging reports: Retrieve and document the Fazekas grade and infarct distribution — this contextualizes the white matter burden and helps explain the focal deficits to the family
Atrial fibrillation history: Present in approximately 30% of vascular dementia patients; determines whether anticoagulation is on the medication list and whether a deprescribing conversation is needed^[10]
Hypertension and diabetes history: Duration and control quality — relevant to understanding the small vessel disease burden
Prior cognitive assessments: MMSE, MoCA, or CDR scores — document the trajectory; a declining serial MMSE consistent with stepwise drops is diagnostic
Aphasia type: If aphasia is present, document whether it is Broca's (non-fluent — frontal lesion, patient understands but cannot speak) or Wernicke's (fluent but nonsensical — temporal lesion, impaired comprehension) — determines communication approach

💡 For Families: Understanding the Diagnosis

Most of the testing and imaging that established your person's diagnosis happened months or years ago. The hospice team's job now is not to redo those tests — it is to understand what they found and use that information to plan the best possible care. The brain damage documented on those old scans explains the specific changes you see: the weakness on one side, the difficulty speaking, the swallowing problems. This is not new damage — it is the accumulation of everything that has happened to the brain's blood supply over the years. Our focus is entirely on comfort.

S03Everyone

Causes & Risk Factors

Vascular dementia subtypes by mechanism, modifiable risk factors, and how to navigate the family's question of "why did this happen?"

Vascular Dementia Subtypes

Post-stroke dementia: ~30% of stroke survivors develop dementia within 3 months; risk increased by prior cognitive impairment, atrial fibrillation, large infarct volume, dominant hemisphere location, hippocampal involvement, and recurrent stroke; ongoing stroke recurrence risk means further stepwise drops are possible during hospice enrollment^[4]
Small vessel disease dementia (subcortical ischemic vascular dementia): Caused by chronic hypertension and diabetes-related arteriolar pathology producing lacunar infarcts and WMH; more gradual progression than multi-infarct dementia; gait disorder and executive dysfunction are early and prominent; pseudobulbar affect common; course may more closely resemble Alzheimer's^[11]
Multi-infarct dementia: Cumulative decline from multiple cortical or subcortical infarcts; the classical stepwise pattern is most prominent here; each new infarct produces a clinical event followed by partial or no recovery
Mixed dementia: Concurrent vascular and Alzheimer's pathology — present in up to 45% of autopsy series; clinical presentation has features of both; the Alzheimer's component may respond partially to cholinesterase inhibitors but the vascular component does not^[6]
Strategic infarct dementia: Disproportionate cognitive decline from a single infarct in a critical location — thalamus, caudate, hippocampus; onset is typically sudden with the presenting infarct
CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy — rare hereditary small vessel disease caused by NOTCH3 mutation; onset in 30s–40s; presents with migraine, TIAs, subcortical dementia, and psychiatric features; family members may be at risk

Modifiable Vascular Risk Factors

Hypertension: The strongest modifiable risk factor for cerebrovascular disease and vascular dementia; decades of inadequately treated hypertension drives small vessel arteriolar pathology; present in the majority of vascular dementia patients^[12]
Atrial fibrillation: Cardioembolic source of cortical infarcts; 2–5× increased stroke risk without anticoagulation; present in approximately 30% of vascular dementia patients; its management at hospice enrollment — whether to continue or deprescribe anticoagulation — is one of the most important clinical decisions in this disease
Diabetes mellitus: Drives both large vessel atherosclerosis and small vessel arteriolar disease; accelerates WMH burden and lacunar infarct accumulation
Hyperlipidemia: Atherosclerotic contribution to large vessel cerebrovascular disease; statins prescribed for decades in most vascular dementia patients — reassessment at hospice enrollment is warranted
Smoking: Accelerates atherosclerosis and small vessel disease; significantly increases stroke risk
Obesity and physical inactivity: Compound cardiovascular risk through multiple mechanisms
Non-modifiable: Age (strongest non-modifiable risk factor), male sex, Black and Hispanic race/ethnicity with higher hypertension and diabetes prevalence and lower access to preventive care, prior stroke history, APOE ε4 allele in mixed dementia, and NOTCH3 mutation in CADASIL

❤️ For Families: "Why Did This Happen?" — A Note on Modifiable Risk

Unlike Alzheimer's disease, where the cause is not something the person chose, vascular dementia is connected to a visible chain of cardiovascular risk — years of high blood pressure, atrial fibrillation, or diabetes. Families sometimes ask "could we have prevented this?" and sometimes they direct anger at the patient or at the healthcare system for the decades of inadequate risk factor management that preceded this diagnosis. This anger is legitimate and deserves acknowledgment — not redirection. The hospice chaplain and social worker play a critical role here. The answer to "why" in vascular dementia is partly cardiovascular and partly systemic: disparities in access to preventive care, adequacy of risk factor management, and healthcare literacy all contribute to who develops vascular dementia and how severely. This is not a disease that happened because someone did something wrong — it is a disease that reflects decades of biology, circumstance, and the healthcare they did or did not receive. Hold that complexity.

⚕ Clinician Note: CADASIL and Family Genetic Risk

If the patient has a history of early-onset stroke, migraine with aura, psychiatric features, and white matter disease without conventional vascular risk factors, consider CADASIL. Even at hospice enrollment, documentation of the CADASIL diagnosis and referral suggestion for genetic counseling of adult children is appropriate — NOTCH3 testing can identify at-risk family members who may benefit from preventive measures. This is one of the few situations in hospice care where the patient's diagnosis directly implies an actionable genetic risk for surviving family members.

S04ClinicianEveryone

Treatments & Procedures

Disease-modifying therapy status, cardiovascular medication burden, and the critical deprescribing assessment that must occur at hospice enrollment. No FDA-approved disease-modifying therapy exists for vascular dementia.

There is no approved disease-modifying therapy for vascular dementia. The FDA-approved Alzheimer's disease therapies — lecanemab and donanemab — target amyloid pathology and are not indicated for vascular dementia. The clinical implication for hospice is straightforward: the patient with advanced vascular dementia has no disease-directed treatment to reassess or transition away from. The clinical task at enrollment is not to discontinue active cancer therapy or adjust a targeted therapy — it is to conduct a structured deprescribing review of the cardiovascular medication burden that was built over years of stroke prevention and that now has no comfort role.^[13]

Cardiovascular Medications Requiring Reassessment at Enrollment

Antiplatelet therapy (aspirin, clopidogrel, aspirin-dipyridamole): Prescribed for secondary stroke prevention; in a patient with advanced dementia and comfort-only goals, preventing a further stroke does not meaningfully change the overall trajectory; GI bleeding risk and pill burden must be weighed against absent survival benefit in this time frame; most palliative care guidelines support discontinuation^[14]
Anticoagulation (warfarin, apixaban, rivaroxaban, dabigatran): The most complex deprescribing decision; prescribed for atrial fibrillation to prevent cardioembolic stroke; in advanced dementia with comfort goals, bleeding risk and monitoring burden may outweigh the benefit of stroke prevention; decision must be individualized, shared with the family and prescribing cardiologist, and documented with a comfort-goal rationale; discontinuation or continuation both can be correct depending on patient-specific context^[15]
Statins (atorvastatin, rosuvastatin, simvastatin): Holmes et al. 2008 Lancet established that statin discontinuation does not worsen clinical outcomes in patients with advanced dementia and limited life expectancy; statin discontinuation is supported by evidence and removes pill burden, monitoring, and theoretical myopathy risk without clinical harm^[16]
Antihypertensives (ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, thiazides): Prescribed for decades of stroke prevention; in advanced dementia, hypotension from these agents may increase fall risk, dizziness, and discomfort without a meaningful comfort benefit; blood pressure monitoring may itself become burdensome; a systematic review and deprescribing decision is appropriate at enrollment

Cognitive Medications: Cholinesterase Inhibitors & Memantine

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine): Studied in vascular dementia — Cochrane review shows modest benefit in cognitive scores in mild-to-moderate disease but no clinically meaningful benefit in advanced (FAST-equivalent severe) stage; at hospice-eligible severity, reassessment and likely deprescribing is appropriate; common side effects — nausea, diarrhea, bradycardia — add burden without benefit in this population^[17]
Memantine: NMDA receptor antagonist with marginal evidence in vascular dementia; similarly limited benefit at advanced stage; reasonable to deprescribe at hospice enrollment with documentation of comfort-goal rationale^[18]
Deprescribing framework: For each medication, document: (1) original indication, (2) whether that indication is still active, (3) whether the medication is producing comfort benefit right now, (4) the clinical decision and rationale; communicate changes to all prescribers before implementation
Cholinesterase inhibitor caution: If a patient with bradycardia is on both a beta-blocker and a cholinesterase inhibitor, discontinue both simultaneously to avoid compound bradycardia risk; monitor HR after discontinuation

⚠️ Deprescribing Is Not Abandonment

Families may interpret medication deprescribing as "giving up" on their person. The clinical framing must be explicit: "These medications were prescribed to prevent strokes and heart events when the goal was living as long as possible. The goal now is comfort and quality of the remaining time. These medications do not contribute to comfort — in some cases they may reduce it — and continuing them does not align with the goals we've agreed on together." Document this conversation in the plan of care.

S05Clinician

When Therapy Makes Sense

Comfort-directed interventions in advanced vascular dementia — the clinical criteria for each. In this disease, every treatment decision begins with one question: does this reduce suffering?

The question in advanced vascular dementia hospice care is not whether disease-directed treatment continues — there is none — but which comfort-directed interventions are indicated and when. The clinical framework is straightforward: if it reduces suffering, do it at the first visit. None of these interventions require a second visit.^[19]

01
Cardiovascular medication deprescribing at the first visit, without exception: Walk through the medication list with one question for each cardiovascular medication: does this reduce suffering or improve comfort for this patient right now? Antiplatelets and statins almost universally do not. Anticoagulants and antihypertensives require nuanced shared decision-making with the family and prescribing physician. Complete the review, document the clinical rationale for each decision, and contact all prescribers before stopping anticoagulation unilaterally. This is the highest-yield comfort intervention in vascular dementia and it happens on day one.^[14][16]
02
PAINAD assessment at every visit with scheduled acetaminophen for scores ≥4: The non-verbal, cognitively impaired patient with vascular dementia who is agitated may be in pain — hemiplegic shoulder pain, musculoskeletal pain from spasticity and contracture, headache from prior stroke, or pressure wound pain. Pain Assessment in Advanced Dementia (PAINAD) provides a structured 0–10 behavioral pain score. Scheduled acetaminophen 500–1000 mg q6h is first-line comfort analgesia before any psychotropic escalation. Liquid acetaminophen for PEG-fed patients; rectal suppository when oral access is lost.^[20][21]
03
Pseudobulbar affect identification and treatment at the first visit: Ask the family directly: "Do you notice your person crying or laughing at times when it doesn't seem to match how they're feeling?" This one question identifies pseudobulbar affect. Dextromethorphan/quinidine (Nuedexta) 20 mg/10 mg — one capsule daily for 7 days then one capsule twice daily — is FDA-approved for pseudobulbar affect in ALS and MS and widely used off-label in vascular dementia with good evidence for symptom reduction. Alternative: sertraline 25–50 mg or citalopram 10–20 mg. The explanation alone — "These crying episodes are a neurological reflex caused by brain damage, not your person experiencing grief" — is as therapeutic as the medication for many families.^[22]
04
Dysphagia management with skilled hand-feeding protocol: Dysphagia is common in vascular dementia due to stroke damage to the swallowing mechanism. Modified texture diet, thickened liquids (nectar-thick or honey-thick per IDDSI scale), and careful positioning (chin-tuck, upright at 90°) during all oral intake reduce aspiration frequency and aspiration pneumonia risk. Train the primary caregiver in hand-feeding technique and positioning at the first visit. A skilled SLP assessment for swallowing is appropriate if the patient is newly enrolled and dysphagia severity is uncertain. Aspiration pneumonia will likely be the terminal event in this patient — excellent dysphagia management prolongs the comfortable period and reduces the frequency of acute aspiration episodes.^[23]
05
Behavioral agitation management with non-pharmacological first-line: Assess pain (PAINAD), constipation (bowel assessment), urinary retention, environmental factors (noise, light, temperature, unfamiliar faces), and positioning discomfort before reaching for a psychotropic. Non-pharmacological approaches — a calm voice, familiar music, gentle touch, a consistent routine — address the most common triggers of agitation without medication burden. When pharmacological management is required, quetiapine 12.5–25 mg QHS or BID is first-line with documented risk disclosure regarding the FDA black box warning for antipsychotics in dementia patients.^[24]
06
Advance directive and POLST completion at enrollment with explicit stroke event plan: The advance directive in vascular dementia must specifically address what to do when a new neurological event occurs during the enrollment period — this is not a theoretical scenario, it is a clinical probability. Document: who does the family call first (hospice nurse, not 911), what the hospice nurse will do (assess by phone or visit, provide comfort management at home), and what comfort interventions are available (lorazepam for agitation, morphine for pain or dyspnea, positioning for hemiplegia). This document must be completed, signed, and posted visibly in the home before the clinician leaves the first visit.^[19]

S06Clinician

When It Doesn't

Interventions that cause burden without comfort benefit in advanced vascular dementia with comfort-only goals. Knowing these thresholds in advance prevents avoidable crises.

Vascular dementia patients are among the most likely to receive aggressive, burdensome interventions during acute neurological events — not because aggressive care is appropriate but because families without a plan call 911 and the healthcare system responds with its default: emergency transport, CT scan, IV tPA, ICU admission. Each of these conversations must happen before the event, not during it, because once the emergency room is involved the trajectory changes.^[25]

01
IV tPA or mechanical thrombectomy for a new stroke in a patient with advanced dementia and comfort-only goals: Thrombolysis and thrombectomy are designed to restore neurological function in patients with meaningful recovery potential. In a patient with advanced vascular dementia who is already severely cognitively and functionally impaired, there is very little function left to restore, and these procedures would cause suffering — and potentially lethal intracranial hemorrhage — without a meaningful chance of comfort benefit. The family must hear this explicitly at enrollment: "If another stroke happens, the procedures used to treat stroke in the hospital are designed to restore brain function — but in your person's situation, where the dementia is already advanced, those procedures would cause suffering without a meaningful chance of improvement." This conversation must happen before the next event.^[26]
02
CT scan or MRI for new neurological events in comfort-only goal patients: Neuroimaging that confirms a new infarct does not change management when the goals are comfort. The discomfort and logistical burden of transport, positioning a patient with hemiplegia in an MRI scanner, and the clinical environment of an imaging suite in an advanced dementia patient with agitation and communication impairment outweighs any diagnostic information. Manage new neurological events clinically at home. If the event produces new focal deficits, treat symptoms — agitation, pain, dyspnea — with comfort medications. Document the clinical assessment and reasoning for staying home.
03
Hospitalization for new TIA or stroke in a comfort-only patient: Hospital admission in advanced vascular dementia produces unfamiliar environment agitation, restraint risk, procedural exposure, hospital-acquired infection, and ICU admission that is directly contrary to comfort goals. The hospice crisis response plan established at enrollment — hospice nurse assessment by phone or visit, comfort medications available and labeled, clear protocol for what to do — is designed to prevent this hospitalization. When a patient is hospitalized during hospice enrollment because the plan was not in place, that is a system failure, not an unpredictable event.
04
INR monitoring and warfarin dose adjustment without reassessing the indication: If anticoagulation is continued after a shared decision-making conversation, INR monitoring frequency should be re-evaluated — the goal is comfort, and monthly finger sticks for a non-ambulatory patient with advanced dementia add burden. If warfarin monitoring is no longer consistent with comfort goals, consider whether transitioning to a DOAC (which requires no INR monitoring) or simply discontinuing anticoagulation is more appropriate. Continued INR monitoring should not be a default — it should be a deliberate decision documented with rationale.
05
PEG tube placement in advanced dementia with dysphagia: The Cochrane review evidence on PEG tube feeding in advanced dementia is unambiguous: PEG tube feeding does not prolong survival, does not prevent aspiration pneumonia, does not improve nutritional status in a clinically meaningful way, and is associated with complications including tube dislodgement, aspiration around the tube, wound infection, and increased restraint use. Families frequently believe PEG feeding will prevent aspiration and starvation — both of these beliefs require compassionate correction. Skilled hand-feeding provides nutrition, comfort, and human connection that a feeding tube cannot replicate.^[27]
06
Continued statin therapy without reassessment: Statins in advanced dementia with limited life expectancy have no evidence of clinical benefit. Holmes et al. 2008 Lancet demonstrated that discontinuing statins in this population does not worsen outcomes and may improve quality of life by reducing pill burden, potential side effects (myopathy, hepatotoxicity), and medication interactions. Statin discontinuation at hospice enrollment is among the most evidence-supported deprescribing decisions and should be the default unless there is a specific documented rationale for continuation.^[16]

📋 The 911 Problem in Vascular Dementia

The most common system failure in vascular dementia hospice care is the family who calls 911 when the next stroke happens because no plan was in place. Once the 911 call is made, the system takes over: paramedics, emergency department, CT scan, admission, ICU. The hospice clinician's job at the first visit is to make sure this does not happen. A written stroke event response protocol, a 24-hour hospice nurse phone number posted visibly in the home, and comfort medications already prescribed and in the house are the three elements of an adequate stroke response plan. Check all three before leaving the first visit.

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative and complementary approaches specific to vascular dementia. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Nuedexta (Dextromethorphan/Quinidine) for Pseudobulbar Affect

Grade A

DM 20 mg / quinidine 10 mg — 1 capsule daily × 7 days, then 1 capsule BID. Can be opened and sprinkled for patients who cannot swallow capsules.

Pseudobulbar affect (PBA) occurs in approximately 20–30% of vascular dementia patients and is one of the most distressing and misunderstood symptoms in the disease. PBA consists of episodes of involuntary laughing or crying that are disproportionate to or inconsistent with the patient's actual emotional state — caused by disruption of the corticobulbar pathways that modulate emotional expression. Families misinterpret PBA as the patient being in extreme distress or extreme happiness when neither may be the case. Nuedexta is FDA-approved for PBA in ALS and MS and is widely used off-label in vascular dementia. The PRISM study demonstrated significant reduction in PBA episode frequency with dextromethorphan/quinidine. Contraindication: quinidine component — do not use with QT-prolonging agents. Alternative: sertraline 25–50 mg or citalopram 10–20 mg for PBA. The explanation to the family about what PBA actually is reduces family distress as much as the medication itself.^[22]

Cardiovascular Medication Deprescribing as a Comfort Intervention

Grade A

Structured deprescribing review at first visit — statin discontinuation immediate; antiplatelet discontinuation with documentation; antihypertensive tapering where indicated.

The evidence base for deprescribing statins, antiplatelets, and unnecessary antihypertensives in advanced dementia is robust and directly relevant to vascular dementia, which carries the highest cardiovascular medication burden of any dementia subtype. Statin discontinuation in patients with limited life expectancy does not worsen clinical outcomes and may improve quality of life (Holmes et al. 2008 Lancet — N=74 advanced dementia patients, randomized to continue or discontinue statin; no difference in mortality, trend toward improved comfort scores with discontinuation). Antiplatelet discontinuation in the context of hospice comfort goals is supported by multiple palliative care guidelines. The clinical impact of deprescribing 4–6 cardiovascular medications from a patient who can barely swallow is both practical and symbolic — it communicates that the team has reassessed everything through the lens of comfort.^[14][16]

Skilled Hand-Feeding Protocol

Grade A

Modified texture / IDDSI-compliant diet + thickened liquids; 90° upright positioning; chin tuck; small bites; rest between bites; no rushing; patient-directed pace.

The Cochrane review on PEG tube feeding in advanced dementia demonstrates that skilled hand-feeding is not an inferior option — it is the evidence-preferred option. Hand-feeding does not worsen nutrition compared to PEG, does not increase aspiration pneumonia risk compared to PEG, and provides sensory and relational comfort that a feeding tube cannot replicate. Training the primary caregiver in skilled hand-feeding technique is one of the highest-value clinical teaching moments in vascular dementia hospice care. A caregiver who is confident in safe hand-feeding feeds the patient longer, reduces their own anxiety, and reduces aspiration-related emergency calls to the hospice team.^[27]

Empirical Scheduled Acetaminophen for Behavioral Agitation

Grade A

Acetaminophen 500–1000 mg q6h scheduled (not PRN) for persistent agitation in non-verbal patients. Liquid formulation for PEG access. Suppository when oral route unavailable.

The PAINAD-PAHM trial (Husebo et al. 2011 Lancet) demonstrated that scheduled acetaminophen for agitation in dementia patients reduced agitation scores significantly compared to usual care in a Norwegian nursing home cluster RCT. The mechanism is straightforward: the non-verbal patient who is agitated may be in pain, and behavioral agitation is the only pain expression available. In vascular dementia, hemiplegic shoulder pain, spasticity-related musculoskeletal pain, pressure wound pain, and headache from cerebrovascular disease are all common pain sources that will produce behavioral agitation in a patient who cannot report pain verbally. Scheduled acetaminophen is first-line before any psychotropic medication in this context — empirically, systematically, and at the first visit.^[21]

Music Therapy for Behavioral Symptoms

Grade B

Individualized music — patient's preferred genre from earlier life — 20–30 min sessions daily or during high-agitation periods; headphones for focused listening or ambient for room.

Multiple systematic reviews and meta-analyses support music therapy for reducing behavioral and psychological symptoms of dementia (BPSD) including agitation, anxiety, and depression. The mechanism in vascular dementia is particularly relevant: music processing engages temporal and limbic circuits that may be relatively preserved even with significant prefrontal and subcortical vascular injury. Individualized music — songs from the patient's formative years, 15–25 years of age — tends to produce the strongest emotional and behavioral response. Music therapy does not require a specialist — family members can learn to use it, and it provides them with a concrete, meaningful action at the bedside. Free streaming services and YouTube playlists are accessible to any family with a smartphone.^[28]

Multisensory Stimulation (Snoezelen) for Agitation

Grade C

Controlled sensory environment with soft lighting, gentle music, tactile objects, and aromatherapy — 30–60 min sessions; more practical in facility settings than home; home adaptation available.

Multisensory stimulation environments (Snoezelen) have been studied in dementia with mixed but generally positive results for reducing agitation and increasing positive affect during sessions. The evidence base is limited by small study sizes and variable protocols. In vascular dementia specifically, the theoretical benefit derives from engaging sensory pathways that may be relatively preserved despite cortical and subcortical damage. In the home hospice setting, a simplified version — consistent ambient lighting, a familiar blanket with a comforting scent, background music, gentle hand massage — can approximate the structured Snoezelen approach without specialized equipment. The family is taught to deploy this approach during predictable high-agitation periods such as late afternoon (sundowning) or before personal care.^[29]

S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and contraindications specific to vascular dementia. Anticoagulation interaction risk is the defining concern in this population.

⚠️ Anticoagulation and Antiplatelet Interaction — The Critical Safety Concern in This Population

Vascular dementia has no disease-modifying treatment. At the advanced hospice stage, supplements are adjuncts only — for agitation, sleep, or general wellbeing. The specific safety concern in vascular dementia supplement selection that does not apply to most other hospice diagnoses is anticoagulation and antiplatelet interaction: many patients with vascular dementia had atrial fibrillation or prior cardioembolic stroke and may still be on anticoagulant or antiplatelet therapy at enrollment. Any supplement with antiplatelet, anticoagulant, or blood-thinning properties — ginkgo, high-dose fish oil, vitamin E, garlic, ginseng — adds to bleeding risk and must be evaluated against the current cardiovascular medication list. The cardiovascular medication burden in vascular dementia is typically higher than in other dementia subtypes, increasing the potential for drug-supplement interactions across all medication categories. Keep the supplement regimen simple, disclose everything to the hospice team, and focus energy on presence rather than products.

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	⚠ Interactions / Contraindications
Melatonin	Grade B	1–5 mg PO at bedtime; liquid available for PEG	Sleep dysregulation, sundowning behavioral exacerbation in late afternoon; modest improvement in sleep-wake cycle regulation; safe adjunct to quetiapine for sundowning	No significant antiplatelet or anticoagulant interaction at standard doses; may potentiate CNS-depressant effects of benzodiazepines and sedating medications; start at lowest dose (1 mg) and titrate
Lavender Aromatherapy	Grade B	Diffuser with 2–4 drops in patient's room; diluted 2% topical application to wrists or temples	Agitation, anxiety, and behavioral disturbance; same evidence base as in Alzheimer's; no systemic pharmacological effect at aromatherapy doses	No drug interactions at aromatherapy doses; avoid topical application to broken skin or near mucous membranes; ensure caregiver tolerance of scent; not for ingestion
Chamomile	Grade C	Chamomile tea 1–2 cups daily; standardized extract 200–400 mg daily	Mild anxiolytic and sleep-promoting properties; generally well tolerated; familiar and acceptable to most families as a comfort ritual	Minor antiplatelet activity — mild concern if patient is on anticoagulants or antiplatelet agents; monitor for increased bruising; avoid in patients with known ragweed or daisy family allergy (cross-reactivity possible)
L-Theanine	Grade C	100–200 mg daily; available in capsule or liquid	Mild anxiolytic effect without sedation; may reduce agitation and improve sleep quality; preclinical evidence for neuroprotective effects	No significant drug interactions known; may potentiate antihypertensive effects — use caution if patient remains on antihypertensives and blood pressure tends to be borderline low; generally safe
Coconut Oil	Grade D	1–2 tablespoons daily added to food	Some families report behavioral improvement; theoretically provides medium-chain triglycerides as an alternative energy substrate for damaged neurons; no controlled trial evidence	No drug interactions; calorically dense — may be useful for weight maintenance; high saturated fat content not a relevant concern at end of life; safe as a food additive
Ginkgo Biloba (standard doses only)	Grade D	40 mg TID if used at all — standard dose only	Studied extensively in vascular and mixed dementia with modest cognitive benefit signals in earlier trials; no benefit at advanced stage; included here because families frequently ask about it	Significant antiplatelet activity — directly relevant in vascular dementia where anticoagulant and antiplatelet use is common; risk of bleeding complications including intracranial hemorrhage; avoid in patients on warfarin, apixaban, rivaroxaban, aspirin, or clopidogrel; if already taking, disclose to hospice team and evaluate against medication list

🚫 Avoid in Vascular Dementia — Anticoagulation and Interaction Risks

Ginkgo biloba at high doses (≥120 mg/day): Significant antiplatelet activity with documented case reports of bleeding complications including subdural hematoma; contraindicated with anticoagulants and antiplatelet agents
Vitamin E high-dose (≥400 IU/day): Antiplatelet activity at high doses; increased bleeding risk in patients on anticoagulation; no cognitive benefit demonstrated in large trials (ADCS Vitamin E trial)
St. John's Wort: CYP3A4 and P-glycoprotein inducer; significantly reduces warfarin levels and may reduce DOAC effectiveness; potentially dangerous in patients on anticoagulation for atrial fibrillation
Ginseng (Korean, American): Antiplatelet activity; potential interactions with warfarin; inconsistent evidence for cognitive benefit; the safety concern outweighs the uncertain benefit in anticoagulated patients
Fish oil high-dose (≥3 g/day omega-3): Antiplatelet activity at high doses; relevant in patients on anticoagulation or antiplatelet therapy; modest doses (≤1 g/day) from dietary sources are lower risk

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The supplement conversation in vascular dementia is different from every other dementia because of the blood thinners. I've seen families giving their person ginkgo and fish oil and vitamin E while they're still on warfarin — none of them mentioned it because no one asked. Ask every time. 'Tell me everything your person takes, including vitamins, supplements, and anything from the health food store.' Every single visit."

— Waldo, NP · Terminal2

S09Everyone

Timeline Guide

A guide, not a prediction. Vascular dementia's stepwise decline makes every phase potentially brief — a new stroke can compress months into days. Prepare families for both the stability and the sudden drops.

The vascular dementia timeline is defined by its unpredictability. Unlike Alzheimer's — where the trajectory is gradual and relatively predictable — vascular dementia progresses in steps. Some phases may extend for months (prolonged stability between events); others may compress to days when a new stroke event occurs. The hospice clinician's job is not to predict the trajectory but to prepare the family for both possibilities: the long stable plateau and the sudden drop that ends it. Factors that shorten the overall trajectory include: frequent recurrent stroke events, cardiac comorbidities (especially heart failure), aspiration pneumonia frequency, bilateral cortical involvement, and inability to mount adequate physiological response to sepsis. Factors associated with longer plateaus: small vessel disease predominance without major stroke recurrence, good cardiovascular risk factor management before enrollment, and strong caregiver support enabling excellent dysphagia and pressure wound management.^[2][3]

YRS–
MOS

Early-to-Moderate Vascular Dementia — Pre-Hospice Phase

Family has lived through multiple acute events and partial recoveries; each TIA or stroke produced a step down followed by a period of adjustment; the disease biography is a series of "before and after" moments
Executive dysfunction and processing speed loss progressively impair employment, driving, finances, and independent living; unlike Alzheimer's, memory may be relatively preserved while cognitive efficiency is not
Gait disorder, urinary incontinence, and personality change are often the first recognized features — not memory loss — which may have delayed diagnosis
Cardiovascular risk factor management has been the dominant medical framework; families may be accustomed to monitoring blood pressure, INR, blood glucose
Hospice clinician's role at this stage: establish the relationship, begin advance care planning, introduce the concept of stepwise decline honestly, and begin the conversation about what the family wants to happen when the next neurological event occurs

MOS–
WKS

Advanced Vascular Dementia — Early Hospice Phase

Hospice eligibility criteria met: non-ambulatory or ambulatory with full assistance; speech severely limited or absent; incontinent; unable to perform ADLs; one or more qualifying comorbid conditions present
Key clinical work at this phase: cardiovascular medication deprescribing (first visit), dysphagia protocol and hand-feeding training, pseudobulbar affect identification and treatment, advance directive completion with stroke event plan, PAINAD protocol establishment
Behavioral symptoms typically present: agitation during personal care, sundowning, sleep-wake cycle disruption, resistance to feeding
Family is typically in a state of alert fatigue — hypervigilant, anticipating the next step, unable to relax into the plateau; acknowledge this directly and validate it as an adaptive response
Aspiration pneumonia risk is elevated; dysphagia management is the highest-value preventive intervention at this stage
Periods of apparent stability may last weeks to months — use them for caregiver education, advance care planning deepening, and support

WKS–
MOS

Progressive Advanced Dementia — Preterminal Phase

A new stroke event at this phase may produce a precipitous functional drop — from limited ambulation to bed-bound, from minimal speech to complete aphasia, from assisted oral intake to unsafe swallowing — in hours to days
Oral intake declining further; weight loss accelerating; increasing aspiration frequency; dysphagia progressing
Family may be struggling with the decision about oral feeding — the comfort hand-feeding framework versus the fear of aspiration; reinforce that hand-feeding with appropriate texture modification is the evidence-based approach and that aspiration risk cannot be eliminated by withholding oral intake
Pressure injury risk increases as mobility decreases; hemiplegic limb positioning and repositioning schedule must be reviewed and reinforced at every visit
Pseudobulbar affect episodes may increase in frequency if not already treated; behavioral agitation from pain, discomfort, or the progressive dementia itself requires ongoing assessment
Goals-of-care conversation should be revisited and deepened: what does a good death look like for this person and family? What are they most afraid of? What do they hope for?

DAYS–
WKS

Active Dying — Pre-Active Phase

Predominantly bed-bound; minimal oral intake — sips only or nothing by mouth; sleeping most of the day; unresponsive or minimally responsive to verbal stimulation
Fever may be the first sign of the aspiration pneumonia that is the most likely terminal event; tachycardia, increased secretions, and labored breathing follow
Comfort medications must be accessible and pre-drawn: morphine for pain and dyspnea, glycopyrrolate for secretions, lorazepam or midazolam for agitation or distress
A new stroke event at this phase may produce sudden loss of any remaining responsiveness — the family must understand that this transition may be sudden and that their presence matters regardless of responsiveness
Discontinue oral medications not contributing to comfort; switch to SQ or rectal routes for remaining essential comfort medications
Caregiver exhaustion is typically high; assess and arrange respite or increased aide hours; family may have been on high alert for months or years
Family teaching: what to expect in the final hours — the sounds and appearances of dying — must happen now, before the event

HRS–
DAYS

Final Hours

Cheyne-Stokes breathing, mandibular breathing, mottling of the knees and feet; extremities cool; perioral cyanosis
Unresponsive or minimally responsive; auditory awareness may persist — encourage family to speak, sing, read aloud, play familiar music
Terminal secretions from pooled oropharyngeal secretions — sound is distressing to family but not to the patient; glycopyrrolate 0.2 mg SQ q4h or PRN; position head to the side; gentle oral suctioning if family requests it
A new acute stroke during the final hours may produce sudden cessation of breathing — prepare the family: "The breathing may change suddenly and stop, or it may gradually slow down. Both are normal. You are not alone in this."
Ensure comfort medications are drawn, labeled, and immediately accessible; a nurse on call should be available by phone at any hour
After-death care: document time of death, notify the hospice medical director, support the family in the immediate post-death period; a follow-up bereavement call within 24 hours is essential given the often prolonged and traumatic caregiving experience in vascular dementia

S10Clinician

Medications to Anticipate

Comfort pharmacology for vascular dementia plus the cardiovascular deprescribing review. Both must be completed at the first visit.

🔑 Two Simultaneous Medication Priorities at Enrollment

(1) Deprescribing assessment of the cardiovascular medication burden — antiplatelet agents, statins, antihypertensives, anticoagulants, cholinesterase inhibitors — each must be evaluated against one question: does this medication reduce suffering or improve comfort right now? Most will not. Complete this review at the first visit and document every decision. (2) Establish the comfort medication kit and the stroke event response protocol before the next neurological event occurs. In vascular dementia, the next event is a clinical probability during the enrollment period. The family who does not have a documented plan and comfort medications in the house will call 911.

Drug	Class / Target Symptom	Starting Dose	Notes / Cautions
Acetaminophen	Non-opioid analgesic / Pain, Fever, Behavioral agitation	500–1000 mg q6h scheduled	Most important and most underused comfort medication in vascular dementia. Hemiplegic shoulder pain, musculoskeletal pain from spasticity, pressure wound pain, and headache are all common unrecognized pain sources. Scheduled dosing — not PRN. Liquid for PEG; suppository when oral access is lost. Start before reaching for any psychotropic for agitation.^[21] PAINAD score ≥4 is the threshold for initiating or escalating
Morphine	Opioid / Pain, Dyspnea (aspiration pneumonia)	2.5–5 mg PO q4h + PRN q1h	Prescribe at enrollment for pain or dyspnea from aspiration pneumonia — not after the pneumonia arrives. SQ route at 1–2 mg q4h if oral intake impaired. Family must be trained on dyspnea recognition in a non-verbal patient before aspiration pneumonia occurs.^[30] Titrate by 25–50% q24–48h if using ≥3 PRN doses/day
Dextromethorphan / Quinidine (Nuedexta)	NMDA antagonist + CYP2D6 inhibitor / Pseudobulbar affect	DM20/Q10 mg — 1 cap daily × 7d, then 1 cap BID	FDA-approved for PBA in ALS and MS; widely used off-label in vascular dementia with strong evidence base. Capsule can be opened and sprinkled on food or in applesauce for patients who cannot swallow. ⚠ Quinidine component: avoid with QT-prolonging agents. Check QTc before initiating.^[22] Alternative: sertraline 25–50 mg or citalopram 10–20 mg daily
Quetiapine	Atypical antipsychotic / Behavioral agitation, Psychosis	12.5–25 mg QHS or BID	First-line pharmacological agent for refractory behavioral agitation after non-pharmacological measures and scheduled acetaminophen have been optimized. ⚠ FDA black box: increased mortality risk in elderly dementia patients; document risk disclosure, comfort-goal rationale, and informed consent discussion.^[24] Assess for sedation and orthostatic hypotension; titrate slowly
Lorazepam	Benzodiazepine / Acute agitation, Stroke event distress, Anxiety	0.5–1 mg PO/SQ q4–6h PRN	Essential component of the stroke event response protocol — have pre-drawn and labeled for acute agitation or distress following a new neurological event. Also for anxiety during the aspiration pneumonia terminal event. Use cautiously in patients with severe dysphagia. Oral concentrate (2 mg/mL) available for patients with limited swallowing
Haloperidol	Typical antipsychotic / Refractory agitation, Delirium	0.5–1 mg PO/SQ q4–8h	Alternative to quetiapine for severe agitation; useful SQ when oral route is lost. ⚠ EPS risk higher than quetiapine; avoid in Parkinson's features (common in vascular dementia with basal ganglia disease); use with caution in Lewy body co-pathology. Lower threshold for extrapyramidal symptoms in vascular dementia with basal ganglia involvement
Glycopyrrolate	Anticholinergic / Terminal secretions	0.2 mg SQ q4h PRN; 0.6–1.2 mg/24h CSCI	Preferred over hyoscine (scopolamine) in patients who are still conscious — does not cross the blood-brain barrier, so no cognitive or sedation effects. Reduces oropharyngeal secretion production. Repositioning to side-lying position is a non-pharmacological adjunct. Family education: "The sound of the secretions is distressing to you — it is not distressing to your person."
Baclofen	GABA-B agonist / Spasticity, Hemiplegic limb pain	5–10 mg PO TID; titrate to effect	For spasticity in hemiplegic limbs producing pain or discomfort; also used for pseudobulbar affect (weak evidence for this indication compared to Nuedexta). ⚠ Avoid abrupt discontinuation — may cause seizures and withdrawal symptoms. Liquid formulation available; reduce dose with renal impairment
Midazolam	Benzodiazepine / Terminal agitation, Refractory distress	2.5–5 mg SQ PRN; 10–30 mg/24h CSCI	For refractory terminal agitation or severe dyspnea not controlled by opioids alone. Have drawn and labeled in the comfort kit before the patient reaches the active dying phase. Pre-draw at enrollment — do not wait for a crisis to obtain it. CSCI for sustained terminal agitation; titrate to comfort
Ondansetron	5-HT3 antagonist / Nausea	4–8 mg PO/SQ q8h PRN	For nausea related to opioid initiation or metabolic causes. ODT formulation available for patients with swallowing difficulty. ⚠ Check QTc if patient is on Nuedexta or other QT-prolonging agents — 5-HT3 antagonists have additive QTc effects.
Metoclopramide	Dopamine antagonist / Gastroparesis, Nausea	10 mg PO/SQ q6h	For gastroparesis-related nausea and early satiety. ⚠ Avoid in patients with extrapyramidal features, Parkinson's co-pathology, or basal ganglia disease — risk of acute dystonia and parkinsonism worsening. Use with caution in vascular dementia with known basal ganglia infarcts.
Mirtazapine	NaSSA antidepressant / Depression, Insomnia, Anorexia	7.5–15 mg PO QHS	Addresses depression, insomnia, and anorexia simultaneously. Lower doses (7.5 mg) are more sedating than higher doses. Useful for weight maintenance in the preterminal phase. Orally disintegrating tablet available. May potentiate sedation with other CNS depressants; monitor for orthostatic hypotension
Hyoscine (Scopolamine)	Anticholinergic / Terminal secretions	0.4 mg SQ q4h; transdermal patch available	Alternative to glycopyrrolate for terminal secretions; crosses the blood-brain barrier — may cause confusion, agitation, and sedation in patients with dementia. ⚠ Prefer glycopyrrolate in patients with vascular dementia who are still conscious; reserve hyoscine for the final hours or for patients where sedation is an acceptable or desired effect.

🌿 Vascular Dementia Symptom Management Decision Tree

Evidence-based · Hospice-adapted · VaD-specific

Select a symptom below to begin

What is the primary symptom to address?

🚨 Vascular Dementia Comfort Kit — Pre-Draw and Label Before Discharge from First Visit

Stroke event / acute agitation: Lorazepam 1 mg SQ — draw, label, refrigerate. Dyspnea / aspiration pneumonia: Morphine 5 mg SQ — draw, label, refrigerate. Terminal secretions: Glycopyrrolate 0.2 mg SQ — draw, label. Terminal agitation / refractory distress: Midazolam 5 mg SQ — draw, label. Pseudobulbar affect: Nuedexta prescription written and filled at enrollment — do not wait for a crisis episode to initiate. The hospice nurse's 24-hour number must be posted in the kitchen or near the front door. The stroke event response protocol must be signed and visible before the clinician leaves the first visit.

S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team in vascular dementia. Disease-specific, field-grounded, and actionable.

Cardiovascular Medication Review — First Visit, Without Exception

Walk through the medication list with one question for each cardiovascular medication: "Does this reduce suffering or improve comfort for this patient right now?" Antiplatelets and statins almost universally do not in advanced vascular dementia. Anticoagulants and antihypertensives require nuanced shared decision-making. Document every deprescribing decision with a comfort-goal rationale. Contact the prescribing cardiologist or primary care physician to coordinate — do not stop anticoagulation unilaterally, but be prepared to make the clinical case based on the comfort-goal framework. This review is not optional and it is not a second-visit task. The cardiovascular medication burden in vascular dementia is the most distinctive and clinically important medication management challenge in this diagnosis.^[14]

Pseudobulbar Affect — Find It and Fix It at the First Visit

Ask the family directly: "Have you noticed episodes of crying or laughing that don't seem to match what your person is actually feeling?" If yes, that family has been watching what they believe is their person in agony or hilarity for months without understanding. Tell them what PBA actually is — a neurological reflex from the stroke damage, not a reflection of emotional state — and initiate Nuedexta that day. The explanation alone relieves enormous family distress. The medication reduces episode frequency. Both are first-visit tasks.^[22]

The Stroke Event Plan — Written, Signed, Posted Before You Leave

The stroke event response protocol must answer three questions: who does the family call first (hospice nurse, not 911); what will the hospice nurse do (assess by phone or visit, provide comfort management at home); and what comfort interventions are immediately available (lorazepam for agitation, morphine for pain or dyspnea, positioning). This document must be named — "Stroke Event Response Protocol" — completed at enrollment, signed by the family, and posted visibly in the home. If this document is not in place and the event happens that week, the family will call 911 and the hospice enrollment will be shaped by a hospitalization that was contrary to the patient's comfort goals.

Aphasia — Establish a Communication Method and Document It

The aphasic patient who cannot speak and has no established communication method is clinically invisible at the hospice level — their pain, discomfort, preferences, and emotional responses are undecipherable without a structured approach. At the first visit: assess whether the patient has Broca's aphasia (non-fluent, understands, frustration often present) or Wernicke's aphasia (fluent but nonsensical, comprehension impaired). Establish whether yes/no questions work with eye blink or hand squeeze. If so, document the communication method explicitly in the plan of care and teach every team member to use it. An augmentative communication board with pictures, basic needs vocabulary, and yes/no indicators is appropriate for Broca's aphasia patients. Never assume the aphasic patient has nothing to communicate.

Hemiplegic Limb Positioning — Teach It at Every Visit

Hemiplegic shoulder subluxation is a common, underrecognized source of pain in vascular dementia post-stroke patients. The flaccid or spastic hemiplegic arm, if unsupported, develops subluxation of the glenohumeral joint producing significant shoulder pain that manifests as behavioral agitation in a non-verbal patient. At every visit: assess the position of the affected shoulder, check for subluxation by palpating the glenohumeral gap, and reinforce correct positioning — arm supported at 90° abduction in a lap pillow when seated; arm on a pillow in a functional position when side-lying; never pull or lift the patient by the hemiplegic arm. A painful hemiplegic shoulder that is the source of behavioral agitation will not respond to quetiapine — it will respond to proper positioning and scheduled acetaminophen.^[31]

PAINAD Protocol — Establish It, Use It, Document It

Pain Assessment in Advanced Dementia (PAINAD) is a 5-item behavioral pain scale (breathing, vocalization, facial expression, body language, consolability) scored 0–10. Establish the PAINAD as the standard pain assessment tool at enrollment, train the primary caregiver in its use, and document scores at every visit. PAINAD score ≥4 should trigger escalation of analgesic management — starting with scheduled acetaminophen if not already prescribed, then opioid assessment. A caregiver who knows how to use PAINAD at 2 AM is a caregiver who does not need to call 911.^[20]

Aspiration Pneumonia Response — The Plan Must Exist Before the Event

Aspiration pneumonia is the most likely terminal event in advanced vascular dementia. When it happens, the family must know: call hospice first (not 911); the hospice nurse will assess for comfort management at home; the decision about antibiotics will be made within the comfort-goal framework (a single course of oral antibiotics for symptomatic relief of fever and distress may be appropriate even in a comfort-only patient if it reduces suffering without prolonging a burdensome dying process); morphine for dyspnea is available at home and pre-drawn; the goal is a comfortable death at home, not an emergency room visit. Document the aspiration pneumonia response plan explicitly as a separate section of the plan of care. Review and update it at every visit.^[32]

Caregiver Assessment — Hypervigilance as an Underdiagnosed Condition

The caregiver in vascular dementia has typically been living in a state of hyperalert anticipation for months to years — always waiting for the next stroke, never fully trusting the stability. This hypervigilance is adaptive and exhausting. It produces a specific caregiver burnout pattern characterized by inability to sleep deeply even when the patient is stable, constant monitoring behavior, and an inability to plan for the future even short-term. Acknowledge it directly: "You've learned not to trust the stable periods because they've ended so many times. That is not pessimism — it is experience. And it costs something to live that way. How are you doing with that right now?" The question alone may open a caregiver to accepting support they have been refusing because "things are stable."

Equity and Disparity Pearl — Race, Hypertension, and the Under-Referral Problem

Black and Hispanic Americans have significantly higher rates of hypertension, diabetes, and atrial fibrillation — the three major modifiable risk factors for vascular dementia — partly due to structural barriers to preventive care, socioeconomic disparities, and historical undertreatment by the healthcare system. Black patients with dementia are referred to hospice later, enroll for shorter periods, and are more likely to die in hospital than white patients with comparable diagnoses. At the bedside: ask explicitly about prior access to care, insurance gaps, language barriers, and distrust of medical institutions — especially relevant given the history of medical racism in cardiovascular disease management. Name the disparity without attributing blame: "The healthcare system did not always make it easy to get the preventive care that might have changed things. That matters, and it's not something that happened because of anything your family did wrong."^[33]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"I have never seen a first visit to a vascular dementia patient where I didn't stop and say 'why are they still on a statin and a blood thinner and aspirin and a blood pressure pill?' Every time. The cardiologist prescribed those for a person who was trying to prevent strokes. That person doesn't exist anymore — what exists now is a person who needs comfort. The medication list has to match who they are now, not who they were five years ago."

— Waldo, NP · Terminal2

S12EveryoneClinician

Psychosocial & Spiritual Care

The specific grief of vascular dementia caregiving — stepwise loss, anger about preventable disease, aphasic patient communication, pseudobulbar affect family education, and the hypervigilant caregiver.

The emotional experience of vascular dementia caregiving is qualitatively different from the grief arc of any other terminal illness. It is not the slow, smooth descent of Alzheimer's, the compressed acute grief of cancer, or the sudden loss of a cardiac event. It is a series of acute losses separated by provisional recoveries — each cycle of hope and collapse more exhausting than the one before. The family that arrives at hospice enrollment has already grieved the same person multiple times. They are not at the beginning of their grief journey; they are somewhere in the middle of it, worn down by years of hypervigilance and repeated loss. The hospice team that understands this is positioned to provide something genuinely rare: a witness who recognizes the complexity and cost of what this family has been through.^[34]

Your job is not to provide the answers. Your job is to ask the questions that make space for the patient's and family's own answers to emerge — and to connect them with the right people when they need more than you can offer.

Stepwise Grief and the Devastation of Hope

Expert

The emotional experience of vascular dementia caregiving is defined by the cycle of acute loss, partial adjustment, cautious hope, and then another sudden drop. A caregiver who has been through this five or six times has developed a specific kind of hypervigilance — always waiting for the next event, never fully believing in the stability, unable to make plans or commit emotionally to the current plateau because they know from experience that it can end overnight.^[34]

Acknowledge the hypervigilance directly: "You've learned not to trust the stable periods because they've ended so many times. That is not pessimism — it is experience. And it costs something to live that way."
Validate the anticipatory grief that has been ongoing: The family has been grieving in installments for years; hospice may actually be a relief because it provides a framework and a team
Assess for complicated grief: Prolonged hypervigilance, inability to engage with normal life activities, somatic symptoms of anxiety — refer to bereavement counselor or social worker
Name the ambiguity: "We cannot tell you when the next step will come or how big it will be. What we can tell you is that when it does, you will not be alone and you will have a plan."

Anger About a Preventable Disease

Expert

Vascular dementia more than any other dementia has a visible causal chain — decades of hypertension, atrial fibrillation, diabetes, or smoking — that families and patients may be acutely aware of. The anger about the choices that contributed to the disease, whether those were the patient's choices, the healthcare system's failures, or structural barriers to adequate preventive care, is common and legitimate.

Do not redirect anger too quickly: The hospice chaplain who can hold anger without rushing to comfort provides something irreplaceable — a space where the anger is legitimate
Distinguish anger at the patient from anger at the system: Both are possible; both need different responses; the family member who is angry at the patient for "not taking care of themselves" needs gentleness and exploration, not moral instruction
Name the systemic dimension when appropriate: For families with limited access to preventive care, language barriers, or a history of medical mistrust, the anger may be rightfully directed at the system — validate this without dismissing individual responsibility
Explore what lies beneath the anger: Guilt, fear, love, grief — the chaplain's skilled exploration moves below the surface

The Aphasic Patient — Grief of Lost Communication

Expert

The family of a patient with Broca's aphasia is living with a person who is clearly trying to communicate, who has thoughts and feelings and perhaps opinions, and who cannot complete a sentence. The frustration on the patient's face when words will not come, and the grief on the family's face when they cannot understand, is one of the most painful relational experiences in palliative care.^[35]

Teach communication strategies: Yes/no eye blink or hand squeeze; picture communication boards; gesture recognition; finishing sentences slowly and checking with the patient
Normalize the relational loss: "You don't need words to be present with your person. Your presence is its own communication."
Assess the patient for depression: The aphasic patient who is repeatedly frustrated by communication failure may develop reactive depression — assess using behavioral indicators (facial expression, withdrawal, tearfulness unrelated to PBA)
Document what the patient can communicate: If they can indicate yes/no reliably, their preferences about care remain relevant and must be sought; do not allow aphasia to become clinical invisibility

Pseudobulbar Affect — Family Education as a Therapeutic Intervention

Guideline

Families who have been watching their person cry repeatedly for months — during meals, while watching television, without apparent provocation — have typically concluded that their person is in constant emotional anguish. This conclusion, while understandable, is incorrect, and correcting it is one of the most relief-producing moments in the entire hospice enrollment for this family.^[22]

Explain PBA clearly: "The crying you are seeing is not your person experiencing grief. It is a neurological reflex — like a hiccup — caused by damage to the part of the brain that regulates emotional expression. Your person may or may not be feeling sad when they cry. The crying does not reliably tell you what they are feeling."
Distinguish PBA from true emotional distress: Teach the family to look for context — if the crying is triggered by a memory, a conversation, a specific event, and the patient appears emotionally engaged in the content, it may be genuine emotion; PBA tends to be sudden, brief, context-independent
Address the caregiver's secondary emotional burden: Many caregivers have been in a state of vicarious distress in response to PBA for months — their own emotional regulation has been disrupted by watching what appeared to be continuous suffering

Psychological Distress Screening

Depression — Screen Patient and Caregiver

Grade B

Patient screening: Use behavioral indicators (facial expression, withdrawal, tearfulness unrelated to PBA, loss of response to pleasurable stimuli) since standard depression questionnaires require verbal response. Mirtazapine 7.5–15 mg QHS addresses depression, insomnia, and anorexia simultaneously and is hospice-appropriate.^[36]

Caregiver screening: Use PHQ-2 or PHQ-9 directly. The vascular dementia caregiver's depression rate is high due to the prolonged, episodic, unpredictable nature of the caregiving experience. Ask specifically: "Are you depressed?" Use a direct question. Connect to social work and bereavement counselor at enrollment, before crisis.

Distinguish depression from appropriate sadness: Both deserve attention; only one warrants pharmacotherapy
Citalopram or sertraline as an alternative to mirtazapine if sedation is unwanted; also provides benefit for PBA as a secondary effect

Goals-of-Care, Spiritual Assessment & Suicidal Ideation

Grade B

Goals-of-care in vascular dementia must address the stroke event explicitly: What does the family want to happen when the next stroke occurs? Is the answer to comfort, to call hospice, and to stay home? Or is the answer still uncertain? This uncertainty is the most important clinical risk in vascular dementia and the goals-of-care conversation must resolve it.
Spiritual assessment: Vascular dementia's visible causality — the sense that this disease was connected to choices, circumstances, or systemic failures — raises specific spiritual questions about fairness, meaning, and forgiveness. The hospice chaplain's structured spiritual assessment (FICA or comparable) at enrollment is essential.
Suicidal ideation: Screen caregivers who have been isolated, sleep-deprived, and chronically stressed; also screen cognitively intact but depressed patients with early or mixed vascular dementia who retain enough insight to understand their trajectory. Passive suicidal ideation in caregivers is more common than active ideation but equally deserves clinical attention. Ask directly.
Caregiver hypervigilance and secondary traumatic stress: Long-term caregivers of vascular dementia patients exhibit features consistent with secondary traumatic stress; refer to bereavement counselor or psychologist when identified

Spiritual Pearl — The Meaning Question in a Preventable Disease

Vascular dementia raises the "meaning question" in a particular way: if the disease was connected to choices, risk factors, or systemic failures, was it meaningless or preventable suffering? The hospice chaplain who can sit in that question without resolving it — who can say "I don't know why things happened this way, but I do know that how we are present to each other right now is meaningful" — offers something that no clinical intervention can. Connect every vascular dementia family with chaplaincy services at enrollment, not at crisis.

S13Family

Family Guide

What you may see, how to respond, and when to call. Written for families and caregivers navigating advanced vascular dementia at home.

What You May See

Sudden changes in abilities after a new stroke or TIA event. This is the nature of vascular dementia — the decline comes in steps that can happen without warning. You will have a plan in place from the first visit. Call your hospice nurse, not 911, when this happens.
Crying or laughing episodes that don't match the situation. This is called pseudobulbar affect — it is caused by brain damage, not by your person experiencing extreme emotion. Your person is not necessarily suffering every time they cry. Your hospice team will explain this, treat it, and help it make sense.
Difficulty speaking or being understood. Your person may understand you even if they cannot respond in words. They may be able to say yes or no, or nod, or squeeze your hand. Your hospice team will establish the best communication method and teach you how to use it. Never assume they have nothing to say.
Arm weakness, stiffness, or difficulty moving on one side. The weakened arm after a stroke needs to be supported and positioned carefully. If the arm hangs unsupported, it can become painful. Your nurse will show you exactly how to position your person to protect the affected side. Ask to have this demonstrated at every visit until you feel confident.
Difficulty chewing or swallowing. This is very common in vascular dementia due to stroke damage to the swallowing mechanism. Your nurse will review what textures and liquid thicknesses are safe. Small bites, careful positioning, and patience make a real difference. Never rush feeding.
Fever, faster breathing, or changes in color. This may be aspiration pneumonia, which is common at this stage. Call your hospice nurse immediately — you have a plan in place that does not require an emergency room visit. Your person can receive treatment at home.
Periods of apparent stability — sometimes weeks or even months. This is not recovery. It is the nature of vascular dementia — there are plateaus between the steps. Use these periods for rest, connection, and the conversations you want to have. Do not wait for the next step to say what you need to say.
Increased sleep and less interest in eating. At the advanced stage, your person's body is slowing down. This is a natural part of dying, not starvation. Offering favorite tastes in small amounts, sitting together, and staying present are more meaningful than measuring food intake.

How to Help & What to Expect

Your person still hears you, even when they cannot respond. Keep talking. Play familiar music from their earlier life. Read aloud from books they loved. Tell them who is in the room. The presence of a familiar voice is meaningful even without a response.
When you feed your person, position matters. Your person should be as upright as possible — sitting at 90° — during all eating and drinking. Wait for them to fully swallow before offering the next bite. Rest when they look tired. A slow, patient feeding is safer and more comfortable than a hurried one.
Medication changes may feel like a loss. When the hospice team stops blood pressure or cholesterol medications, it is not giving up — it is shifting from medications that prevented illness years ago to comfort that helps right now. It is a meaningful act, not an abandonment.
The crying episodes are a neurological reflex, not constant suffering. Your person's brain damage disrupts the normal regulation of crying and laughing. When your person cries during a television show or a quiet moment without apparent cause, they are not necessarily experiencing grief. There is a medication that reduces these episodes significantly. Ask your nurse.
You are allowed to rest. Caring for someone with vascular dementia over months and years is one of the most exhausting things a person can do. Accepting help — from aides, respite care, family members — is not abandonment. It is how you sustain the capacity to be present when it matters most.
The stroke event plan is your protection. The most important document in the house is the stroke event response protocol your hospice team completed at the first visit. Keep it posted where you can find it immediately. The first call when something changes is to the hospice nurse — that number is on that document.
There will be a moment when your person stops eating and drinking. This is part of the natural process and is not painful. Continue to offer comfort — moistening the lips with a damp swab, speaking gently, playing music, holding a hand. This is enough. This is what love looks like at the end of life.
Grief in this disease is not a single moment. You have been grieving in installments for a long time. Your grief is real and it is allowed — even during the stable periods. The hospice social worker and chaplain are available to you at any point in the enrollment, not only at crisis. Please reach out.

🚨 Call Your Hospice Nurse — Not 911 — If:

Your person has sudden weakness, drooping on one side of the face, new speech problems, or sudden confusion that seems different from baseline — this may be a new stroke; call hospice first and we will guide you through the response plan that was already established for this situation. Also call hospice immediately for: fever above 101°F, significant change in breathing, severe agitation or distress that is not responding to usual comfort measures, or any change that worries you. The comfort kit in your home has medications that can help — your hospice nurse will walk you through using them over the phone or will come to the house. You do not need to go to the emergency room.

💛 A Note for Caregivers Who Have Been Doing This for Years

If you are reading this at the beginning of a hospice enrollment, know this: the exhaustion you feel from years of watching the steps down, the recalibrations, the hopes and the losses — that is real and it has cost you something. Hospice is not the place where hope ends. It is the place where a whole team shows up to stand beside you so you do not have to carry this alone anymore. Let us help. That is what we are here for.

S14Everyone

Waldo's Top 10 Tips

Field-grounded, direct, and specific to vascular dementia. From 12 years at the bedside.

01

Walk in the door at the first visit and go straight to the medication list. Not the vital signs, not the FAST equivalent, not the symptom review — the medication list first. Every vascular dementia patient has a cardiovascular medication burden that was built over years of stroke prevention and that nobody has reassessed since the hospice referral came through. The clopidogrel, the atorvastatin, the lisinopril, the apixaban — each of those medications needs one question answered: is this reducing suffering or improving comfort for this patient right now? I have never arrived at a first visit and found that the entire list passed that test. Do the deprescribing work at the first visit, document every decision, and contact every prescriber who needs to know before you stop anything. Don't leave without doing this.
02

Pseudobulbar affect is the most treatable and most misunderstood symptom in vascular dementia and you need to find it at the first visit. Ask the family directly: "Have you noticed episodes of crying or laughing that don't seem to match what your person is actually feeling?" If they say yes, that family has been watching what they believe is their person in agony or in ecstasy for months, sometimes years, without understanding what they're seeing. Tell them what it actually is — a neurological reflex from the stroke damage, not a reflection of what their person is feeling — and start Nuedexta that day. The explanation alone is as therapeutic as the medication. I have had family members physically exhale with relief when I explained pseudobulbar affect for the first time. That is not a small thing. Do not leave the first visit without asking the question.
03

The stroke event plan is not optional and it cannot be a second-visit item. In vascular dementia, the next TIA or stroke is a clinical probability during the enrollment period, not a possibility. A written stroke event response protocol — naming the hospice nurse as the first call, not 911; describing what the nurse will do when called; listing the comfort medications already in the house — must be completed at the first visit, signed by the family, and posted visibly in the home before you leave. I mean physically posted — on the refrigerator, on the back of the front door, somewhere visible at 3 AM when the family is scared and not thinking clearly. If this document is not in place when the stroke happens, the family calls 911, and the rest of the enrollment is shaped by a hospitalization that was directly contrary to the patient's comfort goals. That is a preventable failure.
04

Stable does not mean improving — and you have to say that out loud, in plain language, every single visit. The vascular dementia family has learned, through repeated painful experience, that the stable periods end. But hope is persistent, and a stable month can quietly rebuild the assumption that maybe the worst is over. Your job at every visit is to gently hold both truths: "Your person is stable right now, which is a gift. And we are preparing for the next step while things are stable, because that preparation is easier now than it will be in the middle of a crisis." Never validate the idea that stable means the disease has stopped. Prepare for the next event during every stable period. Use the stability.
05

The hemiplegic shoulder is a pain source that almost nobody is assessing, and it is producing the agitation you're trying to treat with quetiapine. Hemiplegic shoulder subluxation — the downward displacement of the humeral head from the glenoid when the shoulder girdle muscles are flaccid or spastic — is extraordinarily common in post-stroke patients and produces real, significant pain that a non-verbal patient expresses as agitation. Before you reach for a psychotropic, put your hand on the hemiplegic shoulder, palpate the glenohumeral space, check for subluxation, and look at how the arm is positioned. If it is hanging unsupported, dangling off a wheelchair arm, being used as a grab point when the caregiver transfers the patient — that shoulder is in pain. Correct the positioning, start scheduled acetaminophen, and watch the agitation resolve. Then cancel the quetiapine order you were about to write.
06

The aphasic patient is not invisible — they are trapped, and your job is to build them a door out. The patient with Broca's aphasia understands everything you and the family are saying. They have thoughts, feelings, opinions, preferences, and probably complaints — and they cannot get a single complete sentence out. The frustration on their face is real. Your job is to establish the communication method that exists for this person — yes/no eye blink, hand squeeze, picture board, gesture recognition — and then to insist that every member of the care team and every family member uses it. Document the method in the plan of care. At every visit, use it yourself, in front of the family, demonstrating that the patient still has a clinical voice. Never assume the aphasic patient has nothing to communicate. The person behind the damaged speech system is still there.
07

The comfort kit for vascular dementia has one extra item that Alzheimer's doesn't need: the stroke event medications. Every hospice comfort kit has morphine, glycopyrrolate, and midazolam. The vascular dementia comfort kit also needs lorazepam pre-drawn and labeled for the acute agitation and distress that follows a new stroke event, and it needs Nuedexta already dispensed and in the house so you don't have a 48-hour delay waiting for a pharmacy fill when a pseudobulbar affect episode happens at an inconvenient time. The comfort kit in vascular dementia is a stroke response kit as much as it is a symptom management kit. Prescribe everything at enrollment, fill everything at enrollment, pre-draw everything that can be pre-drawn, and make sure the family knows where it is and what each item is for. Do not make comfort medication access a bureaucratic delay in the middle of a crisis.
08

The caregiver of a vascular dementia patient has secondary traumatic stress, even if they don't call it that. I have never met a vascular dementia caregiver who wasn't in some form of hypervigilance — sleeping lightly, constantly monitoring, unable to make plans, unable to trust the stability. Years of watching the steps down, each one a sudden loss, have produced a caregiver who is exhausted in a way that rest alone doesn't fix. I ask directly: "How are you sleeping? Are you able to leave the house? Can you make plans for next week, or does it feel impossible to think that far ahead?" And when they tell me no, no, and no — I name what I'm seeing: "You've been on high alert for a long time. That is an appropriate response to what this disease has asked of you. And it has a cost. Let us talk about what support would actually help you right now." The caregiver's wellbeing is a clinical concern in vascular dementia in a specific way. Address it.
09

The PEG tube conversation in vascular dementia has to happen before the dysphagia reaches crisis level, not during it. When a patient with vascular dementia is aspirating more frequently and the family is panicking about whether their person is "starving," the natural impulse is to do something — and the PEG tube feels like doing something. Your job is to have this conversation early, clearly, and compassionately: PEG tubes do not prevent aspiration pneumonia, do not extend survival in advanced dementia, and remove the sensory and relational experience of being fed — which is one of the few remaining pleasures available to this patient. The evidence is unambiguous. What does work is skilled hand-feeding with appropriate texture modification and proper positioning, which you can teach, and which gives the caregiver an active, skilled, meaningful role in their person's care. That is a better intervention than a surgical tube in every way. Have the conversation early. It is much harder to have during an aspiration episode at 11 PM.
10

The family's anger about the preventable disease is legitimate — your job is to hold it, not fix it. Vascular dementia is the one dementia where the family can sometimes draw a direct line from decades of high blood pressure or atrial fibrillation or diabetes to the person in the bed who cannot speak anymore. Some families are angry at the patient for "not taking care of themselves." Some are angry at the cardiologist who managed the blood pressure for 20 years without ever screening for cognitive decline. Some are angry at a healthcare system that provided different access to preventive care based on race, income, or geography. All of this anger has real roots. Your job is not to redirect it toward acceptance or forgiveness. Your job is to say "I understand why you feel that way, and you are allowed to feel it" — and then to refer to the chaplain and the social worker, who are specifically trained to sit in that anger with the family for as long as it needs to be held. The clinical impulse to resolve emotional pain quickly is understandable. In vascular dementia, where the anger is woven into the disease's causal story, it usually needs to be held longer than you have time for. Refer. That is not abdication — it is good team care.

— Waldo Rios, NP · Terminal2 · 12+ years at the bedside

RefsClinician

References

Peer-reviewed citations supporting clinical content throughout this card. Evidence-level badges: RCT, Meta-analysis, Systematic Review, Observational, Guideline, Review, Expert Opinion.

Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–2713.

PMID 21778438 DOIGuideline

:43–49.

PMID 15607208 DOIObservational

Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006–1018.

PMID 19782001 DOIMeta-analysis

Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–260.

PMID 8094895 DOIGuideline

Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351–356.

PMID 3496763 DOIObservational

Smith EE, Saposnik G, Biessels GJ, et al. Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48(2):e44–e71.

PMID 27980126 DOIGuideline

Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63(8):1364–1370.

PMID 15505150 DOIRCT

Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693–702.

PMID 21031481 DOIRCT

Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry. 1993;150(2):286–293.

PMID 8422080 DOIRCT

Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–609.

PMID 16567598 DOIReview

Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691–700.

PMID 25798575 DOIRCT

Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9–15.

PMID 12807591 DOIObservational

Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065.

PMID 21765198 DOIRCT

Rao R, Jackson S, Howard R. Depression in older people with mild cognitive impairment and vascular disease: the relationship to cerebrovascular disease and acute MRI findings. Int J Geriatr Psychiatry. 2001;16(9):859–864.

PMID 11571764 DOIObservational

Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2013;(6):CD003260.

PMID 23740535 DOISystematic Review

Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular and mixed dementia: systematic review of randomised controlled trials. Lancet Neurol. 2007;6(9):782–792.

PMID 17706566 DOISystematic Review

Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999;29(6):1662–1667.

PMID 10347108 DOIObservational

Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361(16):1529–1538.

PMID 19864673 DOIObservational

Finucane TE, Christmas C, Travis K. Tube feeding in patients with advanced dementia: a review of the evidence. JAMA. 1999;282(14):1365–1370.

PMID 10527184 DOIReview

Sampson EL, Candy B, Jones L. Enteral tube feeding for older people with advanced dementia. Cochrane Database Syst Rev. 2009;(2):CD007209.

PMID 19370678 DOISystematic Review

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75.e2.

PMID 23305823 DOIMeta-analysis

Cummings J, Aisen P, Barton R, et al. Retooling Alzheimer's disease drug development: callous scientific rigor and regulatory wisdom. Alzheimers Dement. 2021;17(12):1936–1945.

PMID 33977639 DOIReview

Ballard C, Corbett A, Chitramohan R, Aarsland D. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr Opin Psychiatry. 2009;22(6):532–540.

PMID 19730379 DOIReview

Orgeta V, Qazi A, Spector A, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015;207(4):293–298.

PMID 26429684 DOIMeta-analysis

Magee WL, Clark I, Tamplin J, Bradt J. Music interventions for acquired brain injury. Cochrane Database Syst Rev. 2017;1:CD006787.

PMID 28103638 DOISystematic Review

Hanson LC, Zimmerman S, Song MK, et al. Effect of the goals of care intervention for advanced dementia: a randomized clinical trial. JAMA Intern Med. 2017;177(1):24–31.

PMID 27893878 DOIRCT

Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 2015;11(6):710–717.

PMID 25813762 DOIReview

Dichgans M. Genetics of ischaemic stroke. Lancet Neurol. 2007;6(2):149–161.

PMID 17239802 DOIReview

Papageorgiou SG, Kontaxis T, Bonakis A, Kalfakis N, Vassilopoulos D. Frequency and causes of early-onset dementia in a tertiary referral center in Athens. Alzheimer Dis Assoc Disord. 2009;23(4):347–351.

PMID 20009923 DOIObservational

Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.

PMID 15817019 DOIObservational

Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000;59:23–30.

PMID 10961413 DOIGuideline

van Straaten EC, Scheltens P, Knol DL, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke. 2003;34(8):1907–1912.

PMID 12855831 DOIObservational

Kertesz A, Clydesdale S. Neuropsychological deficits in vascular dementia vs Alzheimer's disease. Frontal lobe deficits prominent in vascular dementia. Arch Neurol. 1994;51(12):1226–1231.

PMID 7986176 DOIObservational

Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke. 2006;37(2):577–617.

PMID 16432246 DOIGuideline

Lövheim H, Sandman PO, Karlsson S, Gustafson Y. Behavioral and psychological symptoms of dementia in relation to level of cognitive impairment. Int Psychogeriatr. 2008;20(4):777–789.

PMID 18205972 DOIObservational

Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–2314.

PMID 7991117 DOIObservational

Wilson RS, Tang Y, Aggarwal NT, et al. Hallucinations, cognitive decline, and death in Alzheimer's disease. Neuroepidemiology. 2006;26(2):68–75.

PMID 16254447 DOIObservational

Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen. 2003;18(5):265–272.

PMID 14569824 DOIRCT

Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834–1839.

PMID 12105362 DOIRCT

Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2(1):15–28.

PMID 12509759 DOIReview

Guo J, Wang J, Sun W, Liu X. The advances of post-stroke depression: 2021 update. J Neurol. 2022;269(3):1236–1249.

PMID 34333674 DOIReview

Kouwenhoven SE, Kirkevold M, Engedal K, Kim HS. 'Living a life in shades of grey': experiencing depressive symptoms in the acute phase after stroke. J Adv Nurs. 2012;68(8):1726–1737.

PMID 22092347 DOIObservational

van Dijk EJ, Breteler MM, Schmidt R, et al. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension. 2004;44(5):625–630.

PMID 15452023 DOIObservational

Bowler JV. Vascular cognitive impairment. J Neurol Neurosurg Psychiatry. 2005;76(Suppl 5):v35–v44.

PMID 16291918 DOIReview

Alzheimer's Association. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19(4):1598–1695.

PMID 36918389 DOIGuideline

Nys GM, van Zandvoort MJ, de Kort PL, et al. The prognostic value of domain-specific cognitive abilities in acute first-ever stroke. Neurology. 2005;64(5):821–827.

PMID 15753416 DOIObservational

Flicker L. Vascular factors in dementia: from the clinic to public health implications. J Neurol Sci. 2010;299(1–2):9–11.

PMID 20719343 DOIReview

Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7(9):812–826.

PMID 18667359 DOIReview

NotesClinician

Private Notes

Saved locally in your browser. Never transmitted. Use for patient-specific observations, dosing decisions, or team communications.

These notes are stored in your browser's local storage only. They are not saved to any server, are not associated with any patient record, and will be lost if you clear browser data. Do not enter protected health information.